Radio-frequency ablation (RFA) has been indicated as a curative treatment for early-stage hepatocellular carcinoma (HCC). This study was to assess the long-term survival result and analyse risk factors of percutaneous Radiofrequency Ablation with Cool-tip in HCC patients.Methods
A prospective study involved 105 cirrhotic HCC patients (mean tumour size:32,5±11,3 mm) underwent percutaneous RFA using Cool-tip RF electrode (COOL-TIP E SERRIES,COVIDIEN) at the 108 hospital, from September 2012 to December 2017). The Kaplan-Meier curves and the multivariate Cox regression analysis were used to assess the prognostic factors.Results
The progression-free survival (PFS) was 23.6±1.2 months and the overall survival (OS) was 40.3±0.74 months. The cumulative 1 year, 2 year, 3 year, 4 year survival probability were 98%; 95.2%; 87,3% and 70,1 respectively. The PFS was related to tumour morphology, HCC differentiation BCLC staging. The OS were affected by tumour characteristics, number of tumour, AFP response, and tumour complete response. Pre-treatment elevated AFP, multifocal HCCs, non-response AFP, in-complete tumour necrosis were negative prognostic factors for long-term survival. The OS and survival rates were also related to Child Pugh class and stage of tumour. At multivariate analysis (Cox Survival Analysis) tumour size and liver function (Chil-Pugh class) were independent significant predictors of overall patient survival.Conclusions
RFA with Cool-tip electrode is effective for HCC patients; the long-term survival result depends on some prognostic factors before treatment.